

Table 1: Number of subjects: All Specimen Types

	Visit Number							Total
	0	1	2	3	4	5	6	
Material Type								
BLD CLOT	.	4	4	4	.	.	.	12
BUFFY CT	90	37	9	6	.	.	.	142
CELLS	104	83	86	90	76	77	83	599
FFPE TISSUE	.	78	78
PLASMA	430	301	202	137	127	97	87	1381
RBC	.	7	7	6	.	.	.	20
SECRETN	8	.	7	6	.	.	.	21
SERUM	179	89	131	36	27	.	.	462
STOOL	.	6	6	4	.	.	.	16
TISSUE	83	.	42	1	28	.	.	154
TISSUE Preserved in RNAlater	1	2	3
URINE	95	66	68	30	27	.	.	286
WBC	84	53	41	3	.	.	.	181

Table 2: Number of subjects: All Specimen Types, by Study

		Visit Number							Total
		0	1	2	3	4	5	6	
Material Type	Study ID								
BLD CLOT	NWU-Simvastatin/Pancreas	.	4	4	4	.	.	.	12
BUFFY CT	NWU-Endoxifen/Breast	32	29	61
	NWU-Simvastatin/Pancreas	.	7	7	6	.	.	.	20
	NWU-Telapristone/Breast	58	1	2	61
CELLS	Mayo-MUC 1/Colon	104	83	86	90	76	77	83	599
FFPE TISSUE	NWU-4-Hydroxytamoxifen, Tam	.	78	78
PLASMA	Mayo-Erlotinib HCL/Duodenum	67	40	42	3	.	.	.	152
	Mayo-Erlotinib/Liver	23	15	38
	Mayo-MUC 1/Colon	125	101	101	101	100	97	87	712
	NWU-4-Hydroxytamoxifen, Tam	95	81	176
	NWU-Endoxifen/Breast	32	29	61
	NWU-Simvastatin/Pancreas	.	7	7	6	.	.	.	20
	NWU-Telapristone/Breast	60	1	25	86
	UWI-Pomegranate/Prostate	28	27	27	27	27	.	.	136
RBC	NWU-Simvastatin/Pancreas	.	7	7	6	.	.	.	20
SECRETN	NWU-Simvastatin/Pancreas	8	.	7	6	.	.	.	21
SERUM	Mayo-Erlotinib HCL/Duodenum	67	39	42	3	.	.	.	151
	Mayo-Erlotinib/Liver	23	15	38
	NWU-Simvastatin/Pancreas	.	7	7	6	.	.	.	20
	NWU-Telapristone/Breast	61	1	55	117
	UWI-Pomegranate/Prostate	28	27	27	27	27	.	.	136
STOOL	NWU-Simvastatin/Pancreas	.	6	6	4	.	.	.	16

(Continued)

Table 2: Number of subjects: All Specimen Types, by Study

		Visit Number							Total
		0	1	2	3	4	5	6	
Material Type	Study ID								
TISSUE	Mayo-Erlotinib HCL/Duodenum	55	.	42	1	.	.	.	98
	UWI-Pomegranate/Prostate	28	.	.	.	28	.	.	56
TISSUE Preserved in RNAlater	Mayo-Erlotinib/Liver	1	2	3
URINE	Mayo-Erlotinib HCL/Duodenum	67	39	41	3	.	.	.	150
	UWI-Pomegranate/Prostate	28	27	27	27	27	.	.	136
WBC	Mayo-Erlotinib HCL/Duodenum	67	40	41	3	.	.	.	151
	Mayo-Erlotinib/Liver	17	13	30

Table 3: Number of subjects: All Specimen Types, by Site

		Visit Number							Total
		0	1	2	3	4	5	6	
Material Type	Site								
BLD CLOT	Pancreas	.	4	4	4	.	.	.	12
BUFFY CT	Breast	90	30	2	122
	Pancreas	.	7	7	6	.	.	.	20
CELLS	Colon	104	83	86	90	76	77	83	599
FFPE TISSUE	Breast	.	78	78
PLASMA	Breast	187	111	25	323
	Colon	125	101	101	101	100	97	87	712
	Duodenum	67	40	42	3	.	.	.	152
	Liver	23	15	38
	Pancreas	.	7	7	6	.	.	.	20
	Prostate	28	27	27	27	27	.	.	136
RBC	Pancreas	.	7	7	6	.	.	.	20
SECRETN	Pancreas	8	.	7	6	.	.	.	21
SERUM	Breast	61	1	55	117
	Duodenum	67	39	42	3	.	.	.	151
	Liver	23	15	38
	Pancreas	.	7	7	6	.	.	.	20
	Prostate	28	27	27	27	27	.	.	136
STOOL	Pancreas	.	6	6	4	.	.	.	16
TISSUE	Duodenum	55	.	42	1	.	.	.	98
	Prostate	28	.	.	.	28	.	.	56
TISSUE Preserved in RNAlater	Liver	1	2	3
URINE	Duodenum	67	39	41	3	.	.	.	150
	Prostate	28	27	27	27	27	.	.	136

(Continued)

Table 3: Number of subjects: All Specimen Types, by Site

		Visit Number							Total
		0	1	2	3	4	5	6	
Material Type	Site								
WBC	Duodenum	67	40	41	3	.	.	.	151
	Liver	17	13	30

Table 4: Number of subjects: All Specimen Types, by Agent

		Visit Number							Total
		0	1	2	3	4	5	6	
Material Type	Agent								
BLD CLOT	Simvastatin	.	4	4	4	.	.	.	12
BUFFY CT	Endoxifen	32	29	61
	Simvastatin	.	7	7	6	.	.	.	20
	Telapristone	58	1	2	61
CELLS	MUC1	104	83	86	90	76	77	83	599
FFPE TISSUE	4-Hydroxytamoxifen, Tamoxife	.	78	78
PLASMA	4-Hydroxytamoxifen, Tamoxife	95	81	176
	Endoxifen	32	29	61
	Erlotinib	23	15	38
	Erlotinib HCL	67	40	42	3	.	.	.	152
	MUC1	125	101	101	101	100	97	87	712
	Pomegranate	28	27	27	27	27	.	.	136
	Simvastatin	.	7	7	6	.	.	.	20
	Telapristone	60	1	25	86
RBC	Simvastatin	.	7	7	6	.	.	.	20
SECRETN	Simvastatin	8	.	7	6	.	.	.	21
SERUM	Erlotinib	23	15	38
	Erlotinib HCL	67	39	42	3	.	.	.	151
	Pomegranate	28	27	27	27	27	.	.	136
	Simvastatin	.	7	7	6	.	.	.	20
	Telapristone	61	1	55	117
STOOL	Simvastatin	.	6	6	4	.	.	.	16

(Continued)

Table 4: Number of subjects: All Specimen Types, by Agent

		Visit Number							Total
		0	1	2	3	4	5	6	
Material Type	Agent								
TISSUE	Erlotinib HCL	55	.	42	1	.	.	.	98
	Pomegranate	28	.	.	.	28	.	.	56
TISSUE Preserved in RNAlater	Erlotinib	1	2	3
URINE	Erlotinib HCL	67	39	41	3	.	.	.	150
	Pomegranate	28	27	27	27	27	.	.	136
WBC	Erlotinib	17	13	30
	Erlotinib HCL	67	40	41	3	.	.	.	151